English language
NextCell’s Chief Research Officer, Dr. Lindsay Davies, will present the primary efficacy outcome of the ProTrans-2 Phase II study and explain why a single dose of ProTrans can have such long-lasting effects.
On 28 May, NextCell Pharma announced that patients who received a single dose of ProTrans five years ago in the randomized, placebo-controlled Phase II study ProTrans-2 had maintained significantly higher endogenous insulin production than patients who received a placebo.
NOTE
Companies and schedules may change before the event starts. Save the date to your calendar by using Add to calendar.